PUBLISHER: 360iResearch | PRODUCT CODE: 1593022
PUBLISHER: 360iResearch | PRODUCT CODE: 1593022
Intra-abdominal Infections Market by Diagnosis (Abdominal X-ray, Blood Tests, Computed Tomography (CT)), Drugs (Ceftriaxone, Chloramphenicol, Clindamycin) - Global Forecast 2025-2030
The Intra-abdominal Infections Market was valued at USD 22.58 billion in 2023, expected to reach USD 24.57 billion in 2024, and is projected to grow at a CAGR of 8.93%, to USD 41.11 billion by 2030.
Intra-abdominal infections (IAIs) refer to a wide spectrum of pathologies characterized by an inflammatory response of the peritoneum following bacterial or fungal infection. This encompasses conditions like appendicitis, diverticulitis, and peritonitis. The market's necessity stems from a high prevalence of these conditions, a growing aging population, and increasing antibiotic resistance, which demands effective therapeutic and diagnostic solutions. IAIs require timely and precise interventions, underscoring their critical medical application across hospitals and ambulatory surgical centers. Notable market insights reveal that the rising incidence of chronic diseases and the subsequent risk of intra-abdominal infections fuel the market growth for diagnostic tools, such as imaging technologies and laboratory tests, as well as pharmaceutical interventions. Emerging opportunities lie in developing rapid diagnostic kits and potent antibiotics to combat resistant bacterial strains. To seize these opportunities, companies should prioritize partnerships with research institutions and biotechnology firms to foster innovation. However, the market faces limitations like stringent regulatory requirements, high costs of treatment, and delays in diagnosis that prolong inpatient care. Additionally, the diverging reimbursement policies across regions present financial challenges that could stifle growth. Innovation potential thrives in personalized medicine approaches, automated diagnostic technologies, and the exploration of probiotics and microbiota-modulating therapies as preventive strategies. Investing in artificial intelligence for predictive analytics and precision medicine stands as a frontier area for future research, providing data-driven insights for effective treatment protocols. Overall, while the market landscape is riddled with challenges, strategic investments in R&D and collaborative ventures are essential in harnessing the full potential of this evolving sector, ultimately driving better patient outcomes and robust market performance. Understanding these facets equips businesses with actionable insights, supporting enhanced market positioning and sustained growth within the intra-abdominal infection management domain.
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 22.58 billion |
| Estimated Year [2024] | USD 24.57 billion |
| Forecast Year [2030] | USD 41.11 billion |
| CAGR (%) | 8.93% |
Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Intra-abdominal Infections Market
The Intra-abdominal Infections Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.
- Market Drivers
- Intra-abdominal infections resulting in gastrointestinal emergencies
- Rapidly growing pharmaceutical industry, and rise in demand for cost-effective and efficient treatment
- Rowing resistance to antimicrobials such as penicillin and related beta-lactam antibiotics
- Market Restraints
- Penetration of generics resulting in pricing pressure
- Market Opportunities
- Discover of new drugs for the treatment of intra-abdominal infections by pharmaceutical companies
- Increase in public-private partnerships to promote research at academic levels, and awareness about antibiotic therapy
- Market Challenges
- Excessive production capacity of antimicrobials
Porter's Five Forces: A Strategic Tool for Navigating the Intra-abdominal Infections Market
Porter's five forces framework is a critical tool for understanding the competitive landscape of the Intra-abdominal Infections Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.
PESTLE Analysis: Navigating External Influences in the Intra-abdominal Infections Market
External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Intra-abdominal Infections Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.
Market Share Analysis: Understanding the Competitive Landscape in the Intra-abdominal Infections Market
A detailed market share analysis in the Intra-abdominal Infections Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.
FPNV Positioning Matrix: Evaluating Vendors' Performance in the Intra-abdominal Infections Market
The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Intra-abdominal Infections Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.
Strategy Analysis & Recommendation: Charting a Path to Success in the Intra-abdominal Infections Market
A strategic analysis of the Intra-abdominal Infections Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.
Key Company Profiles
The report delves into recent significant developments in the Intra-abdominal Infections Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Ltd., Dr Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Merck KGaA, Mylan Pharmaceuticals Inc., Pfizer Inc., Sanofi SA, Smith & Nephew PLC, Sun Pharmaceutical Industries, Inc., Teva Pharmaceutical Industries Ltd., and Thermo Fisher Scientific Inc..
Market Segmentation & Coverage
This research report categorizes the Intra-abdominal Infections Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Based on Diagnosis, market is studied across Abdominal X-ray, Blood Tests, Computed Tomography (CT), and Ultrasound.
- Based on Drugs, market is studied across Ceftriaxone, Chloramphenicol, Clindamycin, and Metronidazole.
- Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
The report offers a comprehensive analysis of the market, covering key focus areas:
1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.
2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.
3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.
4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.
5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.
The report also answers critical questions to aid stakeholders in making informed decisions:
1. What is the current market size, and what is the forecasted growth?
2. Which products, segments, and regions offer the best investment opportunities?
3. What are the key technology trends and regulatory influences shaping the market?
4. How do leading vendors rank in terms of market share and competitive positioning?
5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Intra-abdominal infections resulting in gastrointestinal emergencies
- 5.1.1.2. Rapidly growing pharmaceutical industry, and rise in demand for cost-effective and efficient treatment
- 5.1.1.3. Rowing resistance to antimicrobials such as penicillin and related beta-lactam antibiotics
- 5.1.2. Restraints
- 5.1.2.1. Penetration of generics resulting in pricing pressure
- 5.1.3. Opportunities
- 5.1.3.1. Discover of new drugs for the treatment of intra-abdominal infections by pharmaceutical companies
- 5.1.3.2. Increase in public-private partnerships to promote research at academic levels, and awareness about antibiotic therapy
- 5.1.4. Challenges
- 5.1.4.1. Excessive production capacity of antimicrobials
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
- 5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental
6. Intra-abdominal Infections Market, by Diagnosis
- 6.1. Introduction
- 6.2. Abdominal X-ray
- 6.3. Blood Tests
- 6.4. Computed Tomography (CT)
- 6.5. Ultrasound
7. Intra-abdominal Infections Market, by Drugs
- 7.1. Introduction
- 7.2. Ceftriaxone
- 7.3. Chloramphenicol
- 7.4. Clindamycin
- 7.5. Metronidazole
8. Americas Intra-abdominal Infections Market
- 8.1. Introduction
- 8.2. Argentina
- 8.3. Brazil
- 8.4. Canada
- 8.5. Mexico
- 8.6. United States
9. Asia-Pacific Intra-abdominal Infections Market
- 9.1. Introduction
- 9.2. Australia
- 9.3. China
- 9.4. India
- 9.5. Indonesia
- 9.6. Japan
- 9.7. Malaysia
- 9.8. Philippines
- 9.9. Singapore
- 9.10. South Korea
- 9.11. Taiwan
- 9.12. Thailand
- 9.13. Vietnam
10. Europe, Middle East & Africa Intra-abdominal Infections Market
- 10.1. Introduction
- 10.2. Denmark
- 10.3. Egypt
- 10.4. Finland
- 10.5. France
- 10.6. Germany
- 10.7. Israel
- 10.8. Italy
- 10.9. Netherlands
- 10.10. Nigeria
- 10.11. Norway
- 10.12. Poland
- 10.13. Qatar
- 10.14. Russia
- 10.15. Saudi Arabia
- 10.16. South Africa
- 10.17. Spain
- 10.18. Sweden
- 10.19. Switzerland
- 10.20. Turkey
- 10.21. United Arab Emirates
- 10.22. United Kingdom
11. Competitive Landscape
- 11.1. Market Share Analysis, 2023
- 11.2. FPNV Positioning Matrix, 2023
- 11.3. Competitive Scenario Analysis
- 11.4. Strategy Analysis & Recommendation
Companies Mentioned
- 1. AstraZeneca PLC
- 2. Boehringer Ingelheim GmbH
- 3. Bristol-Myers Squibb Company
- 4. Cipla Ltd.
- 5. Dr Reddy's Laboratories Ltd.
- 6. Eli Lilly and Company
- 7. GlaxoSmithKline PLC
- 8. Merck KGaA
- 9. Mylan Pharmaceuticals Inc.
- 10. Pfizer Inc.
- 11. Sanofi SA
- 12. Smith & Nephew PLC
- 13. Sun Pharmaceutical Industries, Inc.
- 14. Teva Pharmaceutical Industries Ltd.
- 15. Thermo Fisher Scientific Inc.
LIST OF FIGURES
- FIGURE 1. INTRA-ABDOMINAL INFECTIONS MARKET RESEARCH PROCESS
- FIGURE 2. INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2023 VS 2030
- FIGURE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
- FIGURE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
- FIGURE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 10. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 11. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 12. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 13. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 14. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 15. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 16. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 17. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 18. INTRA-ABDOMINAL INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
- FIGURE 19. INTRA-ABDOMINAL INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023
LIST OF TABLES
- TABLE 1. INTRA-ABDOMINAL INFECTIONS MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 6. INTRA-ABDOMINAL INFECTIONS MARKET DYNAMICS
- TABLE 7. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 8. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ABDOMINAL X-RAY, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT), BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 13. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CEFTRIAXONE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CHLORAMPHENICOL, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY CLINDAMYCIN, BY REGION, 2018-2030 (USD MILLION)
- TABLE 16. GLOBAL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY METRONIDAZOLE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 18. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 19. AMERICAS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 20. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 21. ARGENTINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 22. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 23. BRAZIL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 24. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 25. CANADA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 26. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 27. MEXICO INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 28. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 29. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 30. UNITED STATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 31. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 32. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 33. ASIA-PACIFIC INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 34. AUSTRALIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 35. AUSTRALIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 36. CHINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 37. CHINA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 38. INDIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 39. INDIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 40. INDONESIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 41. INDONESIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 42. JAPAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 43. JAPAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 44. MALAYSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 45. MALAYSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 46. PHILIPPINES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 47. PHILIPPINES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 48. SINGAPORE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 49. SINGAPORE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 50. SOUTH KOREA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 51. SOUTH KOREA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 52. TAIWAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 53. TAIWAN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 54. THAILAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 55. THAILAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 56. VIETNAM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 57. VIETNAM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 58. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 59. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 60. EUROPE, MIDDLE EAST & AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 61. DENMARK INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 62. DENMARK INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 63. EGYPT INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 64. EGYPT INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 65. FINLAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 66. FINLAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 67. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 68. FRANCE INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 69. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 70. GERMANY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 71. ISRAEL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 72. ISRAEL INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 73. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 74. ITALY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 75. NETHERLANDS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 76. NETHERLANDS INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 77. NIGERIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 78. NIGERIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 79. NORWAY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 80. NORWAY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 81. POLAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 82. POLAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 83. QATAR INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 84. QATAR INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 85. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 86. RUSSIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 87. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 88. SAUDI ARABIA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 89. SOUTH AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 90. SOUTH AFRICA INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 91. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 92. SPAIN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 93. SWEDEN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 94. SWEDEN INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 95. SWITZERLAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 96. SWITZERLAND INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 97. TURKEY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 98. TURKEY INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 99. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 100. UNITED ARAB EMIRATES INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 101. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
- TABLE 102. UNITED KINGDOM INTRA-ABDOMINAL INFECTIONS MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
- TABLE 103. INTRA-ABDOMINAL INFECTIONS MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 104. INTRA-ABDOMINAL INFECTIONS MARKET, FPNV POSITIONING MATRIX, 2023
